Patents by Inventor Darren H. Wakefield
Darren H. Wakefield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11879125Abstract: Provided herein, are compositions comprising GaINAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.Type: GrantFiled: March 15, 2023Date of Patent: January 23, 2024Assignee: EMPIRICO INC.Inventors: Darren H. Wakefield, David Rozema, Omri Gottesman
-
Publication number: 20240018523Abstract: Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.Type: ApplicationFiled: December 21, 2021Publication date: January 18, 2024Inventors: Darren H. WAKEFIELD, David ROZEMA, Omri GOTTESMAN
-
Patent number: 11840688Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.Type: GrantFiled: February 19, 2021Date of Patent: December 12, 2023Assignee: Arrowhead Pharmaceuticals, inc.Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
-
Publication number: 20230355654Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.Type: ApplicationFiled: December 21, 2022Publication date: November 9, 2023Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. WOODDELL, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
-
Publication number: 20230355651Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: December 2, 2022Publication date: November 9, 2023Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
-
Publication number: 20230304008Abstract: Disclosed herein are compositions comprising modified oligonucleotides. In some embodiments, the oligonucleotide includes a hydrophobic moiety. In some embodiments, the oligonucleotide includes a vinyl phosphonate. In some embodiments, the oligonucleotide includes modified oligonucleotide sugars such as 2? modified ribose molecules. In some embodiments, the oligonucleotide includes modified internucleoside linkages such as phosphorothioate linkages. In some embodiments, the oligonucleotide includes an siRNA. In some embodiments, the siRNA comprises a duplex region with overhangs on either end.Type: ApplicationFiled: March 27, 2023Publication date: September 28, 2023Inventors: Darren H. WAKEFIELD, Lauren Almeida, David Rozema, Omri Gottesman, David Lewis
-
Publication number: 20230295630Abstract: Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.Type: ApplicationFiled: March 15, 2023Publication date: September 21, 2023Inventors: Darren H. WAKEFIELD, David ROZEMA, Omri GOTTESMAN
-
Patent number: 11590156Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: GrantFiled: August 11, 2020Date of Patent: February 28, 2023Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
-
Publication number: 20230002768Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.Type: ApplicationFiled: June 8, 2022Publication date: January 5, 2023Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. Wooddell, David L. Lewis, Darren H. Wakefield, Lauren Almeida, Steven B. Kanner
-
Patent number: 11534453Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.Type: GrantFiled: September 9, 2020Date of Patent: December 27, 2022Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. Wooddell, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
-
Patent number: 11517584Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: GrantFiled: November 17, 2021Date of Patent: December 6, 2022Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
-
Patent number: 11384355Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.Type: GrantFiled: May 31, 2019Date of Patent: July 12, 2022Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I Wooddell, David L Lewis, Darren H Wakefield, Lauren Almeida, Steven B Kanner
-
Publication number: 20220079973Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: November 17, 2021Publication date: March 17, 2022Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
-
Publication number: 20210189394Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.Type: ApplicationFiled: February 24, 2021Publication date: June 24, 2021Inventors: David B Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
-
Publication number: 20210180066Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.Type: ApplicationFiled: February 19, 2021Publication date: June 17, 2021Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
-
Publication number: 20210100829Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: August 11, 2020Publication date: April 8, 2021Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
-
Publication number: 20210052624Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.Type: ApplicationFiled: September 9, 2020Publication date: February 25, 2021Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. WOODDELL, David B. ROZEMA, David L. LEWIS, Darren H. WAKEFIELD, Lauren J. ALMEIDA
-
Patent number: 10927373Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.Type: GrantFiled: April 16, 2018Date of Patent: February 23, 2021Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
-
Patent number: 10858658Abstract: RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described. Pharmaceutical compositions comprising one or more F12 RNAi triggers together with one or more excipients capable of delivering the RNAi trigger(s) to a liver cell in vivo are also described. Delivery of the F12 RNAi trigger(s) to liver cells in vivo provides for inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.Type: GrantFiled: June 3, 2019Date of Patent: December 8, 2020Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Steven B. Kanner, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
-
Patent number: 10806750Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.Type: GrantFiled: October 1, 2018Date of Patent: October 20, 2020Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. Wooddell, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida